UY32208A - Uso de antigeno de mycoplasma bovis - Google Patents

Uso de antigeno de mycoplasma bovis

Info

Publication number
UY32208A
UY32208A UY0001032208A UY32208A UY32208A UY 32208 A UY32208 A UY 32208A UY 0001032208 A UY0001032208 A UY 0001032208A UY 32208 A UY32208 A UY 32208A UY 32208 A UY32208 A UY 32208A
Authority
UY
Uruguay
Prior art keywords
additional
bovis
cattle
infections
prophylaxis
Prior art date
Application number
UY0001032208A
Other languages
English (en)
Inventor
Beck Michael
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of UY32208A publication Critical patent/UY32208A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Abstract

La presente invención s e refiere a vacunas de combinación y/o al uso combinado de composiciones inmunógenas para el tratamiento y/o profilaxis de ganado contra infecciones microbianas, donde las infecciones están causadas M. bovis y al menos un patógeno relevante de ganado adicional. La vacuna de combinación, como se describe en la presente memoria, comprende al menos un antígeno de M. bovis, preferiblemente el M. bovis atenuado avirulento que se proporciona con la presente memoria y uno o mas componentes inmunológicamente activos adicionales eficaces para el tratamiento y/o la profilaxis de infecciones causadas por un patógeno adicional de ganado adicional
UY0001032208A 2008-10-31 2009-10-29 Uso de antigeno de mycoplasma bovis UY32208A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11028608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
UY32208A true UY32208A (es) 2010-05-31

Family

ID=41435150

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032208A UY32208A (es) 2008-10-31 2009-10-29 Uso de antigeno de mycoplasma bovis

Country Status (15)

Country Link
US (1) US8815255B2 (es)
EP (1) EP2362780B1 (es)
JP (1) JP2012507537A (es)
KR (1) KR20110089260A (es)
CN (1) CN102202685A (es)
AR (1) AR074083A1 (es)
AU (1) AU2009309041B2 (es)
CA (1) CA2740954C (es)
CL (1) CL2011000877A1 (es)
CO (1) CO6361948A2 (es)
MX (1) MX2011004316A (es)
NZ (1) NZ591950A (es)
SG (1) SG10201506597RA (es)
UY (1) UY32208A (es)
WO (1) WO2010051210A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121721A4 (en) * 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
UY31437A1 (es) 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
CN102202685A (zh) 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
RU2606855C2 (ru) * 2010-12-22 2017-01-10 Байер Интеллектчуал Проперти Гмбх Повышение иммунного отклика у видов крупного рогатого скота
US9175049B2 (en) 2012-10-24 2015-11-03 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
WO2014105672A1 (en) 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
BR112016019837A2 (pt) 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores
PL3334454T3 (pl) * 2015-08-14 2023-01-30 Zoetis Services Llc Kompozycje mycoplasma bovis
RU2707289C1 (ru) * 2018-06-07 2019-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ изготовления вакцины, ассоциированной против эшерихиоза, стрептококкоза и псевдомоноза крупного рогатого скота
CN111733094B (zh) * 2020-05-29 2022-09-09 内蒙古民族大学 一种牛源蜡样芽孢杆菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002670A1 (en) 1997-07-10 1999-01-21 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
MXPA02004627A (es) 1999-11-08 2004-02-18 Biomune Vacunas contra el micoplasma bovis y sus metodos de uso.
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
MXPA03011924A (es) 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
RU2004105962A (ru) 2001-08-28 2005-03-27 Пфайзер Продактс Инк. (Us) Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
EP2121721A4 (en) 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY31437A1 (es) 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
NZ589981A (en) 2008-07-03 2012-11-30 Univ Iowa State Res Found Inc Cattle vaccines comprising a disrupted M. bovis bacterium
CN102202685A (zh) 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
CO6361948A2 (es) 2012-01-20
CN102202685A (zh) 2011-09-28
US20120093854A1 (en) 2012-04-19
EP2362780A1 (en) 2011-09-07
CL2011000877A1 (es) 2011-09-16
EP2362780B1 (en) 2019-12-25
AU2009309041B2 (en) 2016-02-04
MX2011004316A (es) 2011-06-16
CA2740954C (en) 2018-09-25
AU2009309041A1 (en) 2010-05-06
JP2012507537A (ja) 2012-03-29
CA2740954A1 (en) 2010-05-06
US8815255B2 (en) 2014-08-26
WO2010051210A1 (en) 2010-05-06
KR20110089260A (ko) 2011-08-05
AR074083A1 (es) 2010-12-22
NZ591950A (en) 2012-12-21
SG10201506597RA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
UY32208A (es) Uso de antigeno de mycoplasma bovis
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
PE20151588A1 (es) Vacuna contra el virus del dengue
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
CO6331297A2 (es) Composiciones adyuvantes novedosas
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
CO6511229A2 (es) Metodos para reducir la actividad viricida en composiciones pcv-2 y composiciones pcv-2 con una inmunogeicidad mejorada
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
BRPI1006452A2 (pt) vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
UY31437A1 (es) Vacuna de mycoplasma bovis y métodos de uso de la misma
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CO2023003242A2 (es) Vacuna contra el coronavirus y procedimiento para la preparación de la misma
MX2018007950A (es) Vacuna multivalente m hyo y usos de la misma.
MX370584B (es) Vacuna contra lawsonia intracellularis y circovirus porcino 2.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
BR112012014689A2 (pt) composição de vacina
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112018069219A2 (pt) uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
AR088908A1 (es) Vacuna

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180919